UK markets close in 3 hours 47 minutes

Senhwa Biosciences, Inc. (6492.TWO)

Taipei Exchange - Taipei Exchange Delayed price. Currency in TWD
Add to watchlist
41.35-0.25 (-0.60%)
At close: 01:30PM CST
Currency in TWD

Valuation measures4

Market cap (intra-day) 3.71B
Enterprise value 2.40B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)3.71k
Price/book (mrq)2.82
Enterprise value/revenue 2.40k
Enterprise value/EBITDA -8.46

Trading information

Stock price history

Beta (5Y monthly) 0.86
52-week change 3-15.45%
S&P500 52-week change 325.59%
52-week high 362.30
52-week low 340.35
50-day moving average 342.76
200-day moving average 346.72

Share statistics

Avg vol (3-month) 3176.11k
Avg vol (10-day) 399.6k
Shares outstanding 589.19M
Implied shares outstanding 690.27M
Float 8N/A
% held by insiders 124.84%
% held by institutions 10.10%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2477.33:1000
Last split date 316 Mar 2020

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-34,628.80%

Management effectiveness

Return on assets (ttm)-12.88%
Return on equity (ttm)-20.22%

Income statement

Revenue (ttm)1M
Revenue per share (ttm)0.01
Quarterly revenue growth (yoy)0.00%
Gross profit (ttm)N/A
EBITDA -309.53M
Net income avi to common (ttm)-296.31M
Diluted EPS (ttm)-3.32
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.32B
Total cash per share (mrq)14.79
Total debt (mrq)9.6M
Total debt/equity (mrq)0.73%
Current ratio (mrq)31.40
Book value per share (mrq)14.77

Cash flow statement

Operating cash flow (ttm)-286.35M
Levered free cash flow (ttm)-187.1M